Cargando…

Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance

BACKGROUND: Eculizumab, a humanized monoclonal antibody targeted to terminal complement protein C5, is approved in Japan for treatment of patients with anti-acetylcholine receptor antibody-positive (AChR+) generalized myasthenia gravis (gMG) whose symptoms are difficult to control with high-dose int...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murai, Hiroyuki, Suzuki, Shigeaki, Hasebe, Miki, Fukamizu, Yuji, Rodrigues, Ema, Utsugisawa, Kimiaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970258/ https://www.ncbi.nlm.nih.gov/pubmed/33796147 http://dx.doi.org/10.1177/17562864211001995

Ejemplares similares

Reappraisal of Oral Steroid Therapy for Myasthenia Gravis
por: Imai, Tomihiro, et al.
Publicado: (2020)

Corrigendum to “Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance”
Publicado: (2021)

Insights into the Classification of Myasthenia Gravis
por: Akaishi, Tetsuya, et al.
Publicado: (2014)

Three Types of Striational Antibodies in Myasthenia Gravis
por: Suzuki, Shigeaki, et al.
Publicado: (2011)

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis
por: Muppidi, Srikanth, et al.
Publicado: (2019)

Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study
por: Jacob, Saiju, et al.
Publicado: (2020)

Association between Glucocorticoid-Induced Osteoporosis and Myasthenia Gravis: A Cross-Sectional Study
por: Konno, Shingo, et al.
Publicado: (2015)

Headache Associated with Myasthenia Gravis: The Impact of Mild Ocular Symptoms
por: Nishimoto, Yoshinori, et al.
Publicado: (2011)

Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis
por: Oyama, Munenori, et al.
Publicado: (2020)

Response to treatment of myasthenia gravis according to clinical subtype
por: Akaishi, Tetsuya, et al.
Publicado: (2016)

Eculizumab: A Review in Generalized Myasthenia Gravis
por: Dhillon, Sohita
Publicado: (2018)

Eculizumab versus rituximab in generalised myasthenia gravis
por: Nelke, Christopher, et al.
Publicado: (2022)

Early fast‐acting treatment strategy against generalized myasthenia gravis
por: Utsugisawa, Kimiaki, et al.
Publicado: (2017)

Correction to: Eculizumab: A Review in Generalized Myasthenia Gravis
por: Dhillon, Sohita
Publicado: (2018)

Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)

Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis
por: Xiao, Hai, et al.
Publicado: (2021)

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis
por: Monteleone, Jonathan P. R., et al.
Publicado: (2021)

Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study
por: Suzuki, Yasushi, et al.
Publicado: (2011)

Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)

Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
por: Vélez-Santamaría, Valentina, et al.
Publicado: (2020)

Consistent improvement with eculizumab across muscle groups in myasthenia gravis
por: Mantegazza, Renato, et al.
Publicado: (2020)

A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
por: Langley, Paul C.
Publicado: (2021)

Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study
por: Nagane, Yuriko, et al.
Publicado: (2017)

Quality of life in purely ocular myasthenia in Japan
por: Suzuki, Shigeaki, et al.
Publicado: (2014)

COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)
por: Muppidi, Srikanth, et al.
Publicado: (2020)

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic
por: Jacob, Saiju, et al.
Publicado: (2020)

Myasthenia Gravis
por: Aarli, Johan A., et al.
Publicado: (2011)

Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan
por: Imai, Tomihiro, et al.
Publicado: (2018)

Eculizumab improved weakness and taste disorder in thymoma-associated generalized myasthenia gravis with anti-striational antibodies: A case report
por: Amano, Eiichiro, et al.
Publicado: (2019)

Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab
por: Mimori, Masahiro, et al.
Publicado: (2022)

Long‐term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses
por: Howard, James F., et al.
Publicado: (2021)

Refractory generalized myasthenia gravis with myasthenic incomplete ophthalmoplegia successfully treated with eculizumab
por: Weidmayer, Sara L., et al.
Publicado: (2023)

Fetal Surveillance in Pregnancies with Myasthenia Gravis
por: Cimpoca-Raptis, Brîndușa Ana, et al.
Publicado: (2021)

Eculizumab during Pregnancy in a Patient with Treatment-Refractory Myasthenia Gravis: A Case Report
por: Vu, Tuan, et al.
Publicado: (2021)

Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis
por: Katyal, Nakul, et al.
Publicado: (2021)

Academic and Employment Status in Patients With Generalized Myasthenia Gravis Treated With Eculizumab: A Case Series
por: Kang, Seung Ah, et al.
Publicado: (2022)

Autoantibodies in Japanese patients with ocular myasthenia gravis
por: Nagaishi, Akiko, et al.
Publicado: (2020)

Safety and effectiveness of eculizumab for adult patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance
por: Kato, Hideki, et al.
Publicado: (2018)

Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance
por: Ito, Shuichi, et al.
Publicado: (2018)

Anemia in female patients with myasthenia gravis
por: Sekiguchi, Koji, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ep1b0f0lo1e1fusqpikl2kgce1